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Specific prophylactic migraine treatments are urgently
needed because of the unmet needs of many
migraine patients. Antibodies targeting calcitonin
gene-related peptide (CGRP) or its receptor have
recently shown efficacy in episodic and chronic
migraine and will be available soon.potential targets for preventive drug development [1, 3].Why do we need new drugs for migraine?
Migraine is a debilitating episodic brain disorder affect-
ing about 15% of the population. Migraine attacks typic-
ally consist of severe, unilateral headaches that are
accompanied by nausea, vomiting and photo- and pho-
nophobia, lasting 4–72 h [1]. The median attack fre-
quency is 1.5 per month, but many patients suffer from
weekly attacks. Migraine is a multifactorial genetic dis-
order for which several dozen gene variants, all with
small effect size, have been identified that suggest the in-
volvement of neuronal and vascular mechanisms in dis-
ease pathology [2]. Similar disease mechanisms, albeit
involving different genes, have surfaced in rare mono-
genic familial hemiplegic migraine (FHM) and in various
monogenic syndromes in which migraine is very preva-
lent among mutation carriers, for example, familial ad-
vanced sleep-phase syndrome (FASPS) and cerebral
autosomal dominant arteriopathy with subcortical in-
farcts and leukoencephalopathy (CADASIL) [2].
Specific acute migraine treatment improved three de-
cades ago with the advent of the ‘triptans’—5-hydroxy-
tryptamine1 (5-HT1) receptor agonists—but not all
patients respond adequately. Attack frequency may* Correspondence: A.M.J.M.van_den_Maagdenberg@lumc.nl
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resulting in a transition from episodic to chronic mi-
graine (defined as 15 or more headache days per month
with at least 8 migraine days). Activation of the trigemi-
novascular system seems pivotal in the generation of at-
tacks. Basic and clinical research revealed that specific
molecules, such as calcitonin gene-related peptide
(CGRP), are increased during attacks, which make themCalcitonin gene-related peptide and its receptor:
drug targets for the treatment of migraine
CGRP is a 37-amino-acid neuropeptide that, together
with its receptor, is located in both the central and the
peripheral nervous system. Besides being a neuromodu-
lator, CGRP is one of the most potent vasodilators
known. The canonical CGRP receptor consists of three
components: calcitonin-like receptor (CLR; a seven-
transmembrane receptor component), receptor activity
modifying protein 1 (RAMP1), and receptor component
protein (RCP) [3]. The involvement of CGRP in mi-
graine was suggested and demonstrated about 30 years
ago by Edvinsson and Goadsby (see [3]). Since then, sev-
eral attempts have been made to develop antimigraine
drugs that inhibit the actions of CGRP. The first ap-
proach was the development of small molecule CGRP
receptor antagonists, the so-called ‘gepants’. These mole-
cules, which are competitive receptor antagonists, were
all effective in the acute treatment of migraine, and some
were successfully tested for the prophylactic treatment
of migraine. Unfortunately, due to pharmacokinetic and
toxicity issues, none of the gepants has reached the
clinic [4]. However, several new gepants are in the clin-
ical phase of development (reviewed in [3, 4]).
Apart from the gepants, antibodies against CGRP
(eptinezumab, fremanezumab, and galcanezumab, which
are humanized antibodies) or the CGRP receptor (erenu-
mab, a fully human antibody) have been developedle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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s—parenteral administration with a long time to achieve
maximal drug concentration (Tmax) and a long plasma
elimination half-life (T1/2)—these drugs are intended for
the prophylactic treatment of migraine. Clinical trials on
all four antibodies have been positive and the tolerability
of the antibodies is excellent, with an adverse event pro-
file similar to that of placebo (see [4]). Recently, the re-
sults of two different phase 3 trials on two of these
antibodies were reported [5, 6].
Goadsby and colleagues [5] described a trial on the
CGRP receptor antibody erenumab in a population of
955 migraine patients with episodic migraine. Patients
received subcutaneous injections of either 70 or 140 mg
erenumab, or placebo, monthly. The primary end point
was a change in mean migraine days per month from
baseline to months 4 through 6. At baseline, the overall
average of migraine days was 8.3 per month. Both doses
of erenumab significantly differed from placebo in the
primary end point; the mean decrease in migraine days
per month was 3.2 (70 mg) and 3.7 (140 mg) days in the
erenumab group and 1.8 days in the placebo group.
A ≥ 50% reduction in the mean number of migraine days
per month was achieved for 43% (70 mg) and 50%
(140 mg) of patients when compared to placebo (27%).
Silberstein and colleagues [6] performed a trial with
the CGRP antibody fremanezumab in 1130 patients with
chronic migraine. Patients received subcutaneous injec-
tions of fremanezumab, in either a quarterly (675 mg at
baseline and placebo at weeks 4 and 8) or a monthly
(675 mg at baseline and 225 mg at weeks 4 and 8) dos-
ing regimen, or matching placebo. The primary end
point was the mean change from baseline in the average
number of headache days per month during the 12 weeks
after the first dose. The mean number of baseline head-
ache days was 13 per month. The mean reduction in
headache days per month was 4.3 and 4.6 for fremane-
zumab administered quarterly or monthly, respectively,
and 2.5 for placebo. A ≥ 50% reduction in the mean
number of headache days per month was achieved for
38% (quarterly) and 41% (monthly) of patients when
compared to placebo (18%).
In accordance with earlier trials, the side effects were
similar for erenumab or fremanezumab and placebo. Al-
though these two trials differ in their patient populations
(episodic vs. chronic migraine), design, and primary end
point, the results seem to indicate a consistent decrease
in headache burden after the use of the antibodies.
Nevertheless, the therapeutic gain vs. placebo (16–23%)
is small.
CGRP mechanisms and challenges
It is interesting to speculate whether there is a clinically
relevant difference between blockade of the receptor(erenumab) or blockade of CGRP itself (eptinezumab,
fremanezumab, galcanezumab). As we described before
[7], this could theoretically be the case because peptides
other than CGRP could bind to the CGRP receptor
when CGRP-binding antibodies are used, and CGRP
might act at receptors other than the CGRP receptor
when the CGRP receptor-binding antibody is used. In-
deed, the amylin1 receptor (calcitonin receptor (CTR)
instead of CLR coupled to RAMP1 and RCP) was re-
cently described to act as a functional CGRP receptor in
the trigeminal system, and probably also in the vascula-
ture [7]. However, there is no evidence at present to
confirm or refute whether there will be a clinically
meaningful difference between these two different
modes of action.
Another relevant question is where the site of action
of the antibodies is located. Because of the large molecu-
lar size of the antibodies (molecular weight of ~
150 kDa), they are unlikely to cross the blood–brain bar-
rier (BBB) in significant amounts. Thus, their point of
action will most probably be located outside the BBB
and could include a vascular site, or neuronal structures
that are not protected by the BBB, such as the trigeminal
ganglion and the paraventricular structures. Indeed, a
vascular action for CGRP seems to be present in, for ex-
ample, the protective mechanism against ischemia
(which is relevant in view of cardiovascular safety [7]) or
hypertension, as has been demonstrated in CGRP-
knockout mice that showed enhanced hypertension in
response to angiotensin II infusion [8]. CGRP might also
affect the migraine phenotype via neuronal pathways, as
evident from experiments in mice overexpressing
RAMP1 neuronally [9]. A clear distinction between the
neuronal and vascular components is difficult, as there
seems to be an intensive crosstalk between these two
systems [10].
Conclusions
The advent of CGRP (receptor)-binding antibodies rep-
resents a valuable novel treatment option for migraine.
In contrast to current prophylactic antimigraine drugs,
this is the first class specifically developed for the treat-
ment of migraine. Although long-term safety remains to
be confirmed, we consider the arrival of the antibodies
as a very positive development. The emergence of this
novel class of drugs is good news, but it is fair to state
that blockade of the CGRP pathway does not seem to be
a panacea for all migraine patients, as response rates are
not perfect. Future research should focus on identifying
characteristics of patients who do not respond to CGRP
(receptor) blockade, for example, genetic factors that de-
termine response. In non-responders, other pharmaco-
logical targets might be explored to establish proper
reduction of migraine attacks. Besides CGRP, other
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relevance in migraine. For example, pituitary adenylate
cyclase-activating peptide (PACAP) and vasoactive intes-
tinal peptide (VIP) have been described as being in-
volved in headache pathophysiology. Novel drugs that
are focused on these targets are currently being devel-
oped [11].
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